Innate Pharma obtains ISO9001:2000 certification for its R&D activity in the field of immunotherapy

Marseille, September 2, 2005 - Innate Pharma, a leading developer of novel anti-tumoral therapies, announced today that it has received ISO9001:2000 certification for its research and development activity in the field of immunotherapy.

This certification marks a new milestone in Innate Pharma's development and occurs at a time when the company is significantly building up its team, enlarging its portfolio of compounds and working on a number of new industry partnerships.

'The ISO9001:2000 certification is undoubtedly a major step forward in Innate Pharma's path to becoming a mature company,' said Hervé Brailly, CEO at Innate Pharma. 'It will be a key asset in winning future industrial and commercial contracts with the pharmaceutical industry.'

'European biotechnology companies that have sought and obtained this certification are few and far between,' said Jacques Beslin, Managing Director of the French certification body AFAQ AFNOR. 'Innate Pharma can be proud of having been through the certification procedure successfully. The award confirms the company's ability to compete on a global scale and that it achieves the tough quality criteria defined by the ISO standard.'

About Innate Pharma: www.innate-pharma.com
Innate Pharma S.A.S., is a French biopharmaceutical company specialized in cancer immuno-therapeutics. It is the first company to develop immuno-modulating agents targeting non-conventional lymphocytes. The company already has several drug candidates in clinical development, including two products in Phase I of clinical development in cancer. The company was founded in 1999, and has raised EUR40 million in private funding since its inception in three rounds of financing. Companies investing in Innate are Novo-Nordisk (Copenhagen), NIF (Tokyo), Quilvest (Paris), Sofinnova Partners (Paris), Alta Partners (San Francisco), GIMV (Anvers), Auriga Partners (Paris), Axa Private Equity (Paris), Gilde Biotech & Nutrition (Utrecht), Pechel Industries (Paris), Innoveris (Marseille) et Inserm-Transfert (Paris). Based in Marseille, Innate Pharma employs 50 staff.
xx

Publisher Contact Information:

Innate Pharma
+44 (0)1273 675100
heidi@ala.com

Company profile of Innate Pharma
Past press releases of Innate Pharma.